Skip to Main Content



The ALS Association

  Monthly e-Newsletter of The ALS Association Greater Sacramento Chapter

March 2017


Chapter News & Upcoming Events

Newsletter Title Banner

Continue Reading

Positive Results for Phase 2/3 Masitinib Clinical Trial Announced

Recently, AB Science announced that the Masitinib phase 2/3 clinical trial reached its primary endpoint of ALSFRS-R in people living with ALS. Currently, the company has applied for conditional marketing approval to the European Medicines Agency (EMA) in Europe and is sharing results with officials at the Federal Drug Administration (FDA) to decide next steps in the U.S. The ALS Association is encouraged by the limited results released by AB Science and looks forward to hearing more later this year. Here is a brief overview of the phase 2/3 Masitinib study.

Continue Reading

New Insights into ALS FUS Mutation Disease Pathways

Mutations in the FUS gene cause familial (inherited) ALS, through unknown mechanisms. Previous research on other ALS-causing genes has shown that those mutant genes harm not only motor neurons, but other types of cells in the central nervous system. That led Dr. Erik Storkebaum of the Max Planck Institute for Molecular Biomedicine in Muenster, Germany, and Drs. Luc Dupuis and Jelena Scekic-Zahirovic, of the University of Strasbourg, France, to ask whether FUS mutations also harm cells besides motor neurons.

Continue Reading

ATLIS Strength Testing May Shorten Clinical Trials

A new study funded by The ALS Association from Dr. Patricia Andres of Massachusetts General Hospital has shown promising results leading to potentially shorter clinical trials. The new test, called ATLIS (Accurate Test of Limb Isometric Strength), is performed in a special chair that is fitted with sensors for muscle strength. Once in the chair, the person completes the entire test without position changes, a benefit for those with ALS.

Continue Reading

Profiles of Milton Safenowitz Postdoctoral Fellows: Dr. Vicente Valenzuela

The Association is pleased to continue on the tradition of supporting bright, young scientists in ALS research through the Milton Safenowitz Postdoctoral Fellowship Program. This year, we are supporting six new postdoctoral fellows out of a highly competitive applicant pool. In this series, we highlight the dedication and unique contribution each fellow makes to ALS research. Today, we feature Dr. Vicente Valenzuela from University of Chile.

Continue Reading

New FYI Factsheet Available Online

A new FYI Factsheet, Information about Mucus Plugs, is now available on our website. The factsheet, written by Lee Guion, MA, RRT, FAARC, provides a informative general overview of mucus and the role it plays, as well as what mucus plugs are, what causes them, and how to prevent them.

Continue Reading

Advocacy Conference Schedule Now Available

The 2017 Advocacy Conference Schedule-at-a-Glance is now available on our website. You can also still register for the conference which takes place May 14 - 16 in Washington, D.C.

Continue Reading

National ALS Registry

Please visit the newly re-designed National ALS Registry section on our website and learn more about the Registry, how to enroll, and much more!

Continue Reading

Learning Opportunities

Untangling the ALS X-Files
Monday, April 17, 2017
2:30 p.m. (ET)

Add to Your Calendar
Webinar Details

ALS Clinical Trial Pipeline Series
Monday, May 22, 2017
4:00 p.m. (ET)

Add to Your Calendar
Webinar Details
Share with a friend:
Stay Connected:

The ALS Association Greater Sacramento Chapter
2717 Cottage Way, Suite 17  Sacramento, CA 95825
(916) 979-9265

View Online  |  Privacy Policy  |  Email Preferences




All content and works posted on this website are owned and copyrighted by The ALS Association. ©2014
Contact the Webmaster